###begin article-title 0
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 54 62 <span type="species:ncbi:9606">Patients</span>
Novel CLCN1 Mutations and Clinical Features of Korean Patients with Myotonia Congenita
###end article-title 0
###begin p 1
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
Myotonia congenita (MC) is a form of nondystrophic myotonia caused by a mutation of CLCN1, which encodes human skeletal muscle chloride channel (CLC-1). We performed sequence analysis of all coding regions of CLCN1 in patients clinically diagnosed with MC, and identified 10 unrelated Korean patients harboring mutations. Detailed clinical analysis was performed in these patients to identify their clinical characteristics in relation to their genotypes. The CLCN1 mutational analyses revealed nine different point mutations. Of these, six (p.M128I, p.S189C, p.M373L, p.P480S, p.G523D, and p.M609K) were novel and could be unique among Koreans. While some features including predominant lower extremity involvement and normal to slightly elevated creatine kinase levels were consistently observed, general clinical features were highly variable in terms of age of onset, clinical severity, aggravating factors, and response to treatment. Our study is the first systematic study of MC in Korea, and shows its expanding clinical and genetic spectrums.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 793 794 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 457 462 <span type="species:ncbi:9606">human</span>
Myotonia congenita (MC) is a form of nondystrophic myotonia characterized by impaired relaxation of skeletal muscle after forceful voluntary contraction or following mechanical or electrical stimulation. MC can be inherited either in an autosomal dominant (Thomsen's disease, OMIM 160800) or an autosomal recessive manner (Becker's disease, OMIM 255700). Regardless of its inheritance pattern, most cases of MC are caused by mutations of CLCN1 encoding the human skeletal muscle chloride channel (CLC-1), which is important for the normal repolarization of muscle action potentials (1, 2). The functional defects caused by CLCN1 mutations impair CLC-1 functions and render the plasma membrane abnormally excitable, leading to clinical myotonia and myotonic discharges on the electromyography (2, 3).
###end p 3
###begin p 4
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
CLCN1 is located on chromosome 7q35 and encompasses 35 kb in genomic DNA with 23 exons (4, 5). To date, more than 120 disease-causing mutations in CLCN1 have been reported, and none appears to have a particularly elevated frequency. They are almost evenly scattered through the gene and include small insertion/deletions, missense, nonsense, and splicing mutations (6). Some of these mutations have been characterized functionally. Many of these mutations are recessive and a compound heterozygous state is presumed in the majority of them, although it has been demonstrated in only a few cases (7).
###end p 4
###begin p 5
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
In this study, we analyzed the DNA of 10 Korean MC patients by sequencing of whole exons of CLCN1 to identify their mutations. We also evaluated clinical features of these patients to understand the genotype-phenotype correlation of CLCN1 mutations.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 7
###begin p 8
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
Ten unrelated Korean patients with MC harboring CLCN1 mutations were included in this study. All of them presented with sudden muscle stiffness accompanied by warm up with use, and showed electromyographic evidence of abnormal excitability of muscle fibers. Two hundred healthy Koreans were also studied as controls. The study was reviewed and approved by Pusan National University Hospital Institutional Review Board and all patients and controls provided written informed consent for DNA acquisition and analysis.
###end p 8
###begin title 9
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
Mutational analysis of CLCN1
###end title 9
###begin p 10
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 683 688 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 723 724 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1324 1331 1309 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 1226 1234 <span type="species:ncbi:9606">patients</span>
To identify the mutations in CLCN1, direct sequence analysis of whole coding regions of CLCN1 was performed. In some patients whose biopsied skeletal muscles were available for the study, reverse transcription-polymerase chain reaction (RT-PCR)-based sequence analysis was undertaken. For RT-PCR, total RNA was isolated from frozen muscle tissue of some patients and reverse transcribed to produce 1 microg of total DNA. The first strand cDNA was then PCR amplified by with the six overlapping cDNA primer pairs that were presently designed. In other patients, DNA was extracted from anticoagulated whole blood and sequence specific primer pairs covering the entire coding region of CLCN1 were used as described elsewhere (4) with minor modification. PCR amplified products were separated on 2% agarose gels, purified, cycle-sequenced with PCR primers using the BigDyetrade mark Terminator Sequencing Kit (Applied Biosystems, Foster, CA, U.S.A.), and electrophoresed using an ABI PRISM(R) 3730XL DNA analyzer (Applied Biosystems). To confirm mutations identified in sequence analysis and to differentiate them from benign polymorphisms, PCR and restriction length polymorphism analysis (PCR-RFLP) was performed using DNA from patients and 200 normal controls. Restriction enzymes used in the PCR-RFLP analysis are listed in Table 1.
###end p 10
###begin title 11
Clinical evaluation
###end title 11
###begin p 12
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">patients</span>
Detailed clinical histories were acquired and standard neurological examinations were performed for all patients with CLCN1 mutations. Historical clinical parameters included age of onset, distribution of muscle stiffness, presence of muscle weakness, provoking factors, and family history. Physical examinations especially focused on the presence of muscle atrophy or hypertrophy, distribution of muscle weakness, status of deep tendon reflexes, and types of maneuvers provoking myotonia. Needle electromyography was performed on at least two different muscles in each extremity. Routine laboratory tests included complete blood count; liver, renal, and thyroid function tests; blood glucose, electrolytes; serum creatine kinase (CK) level; chest radiography; and electrocardiogram. A muscle biopsy was performed on five patients. Biopsied muscles were rapidly frozen in isopentane solution pre-chilled using liquid nitrogen, and were processed for routine histochemical staining reactions including hematoxylin-eosin, modified Gomori trichrome, NADH-tetrazolium reductase, periodic acid-Schiff (PAS), cytochrome oxidase (COX), and ATPase.
###end p 12
###begin title 13
RESULTS
###end title 13
###begin title 14
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
CLCN1 mutations
###end title 14
###begin p 15
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 117 124 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 126 133 126 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figs. 1</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 444 450 444 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 495 501 495 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 555 562 555 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 213 220 <span type="species:ncbi:9606">patient</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
Nine different CLCN1 point mutations were identified; of these, six were novel and have not been reported elsewhere (Table 1, Figs. 1, 2). A single heterozygous mutation was identified in all patients except one (patient 3) who had two heterozygous mutations. All nine identified mutations were point mutations, either missense (n=8) or nonsense (n=1). Two new mutations were shared by two patients respectively: p.S189C in patients 14 and 18 (Fig. 1, panel C) and p.M609K in patients 4 and 10 (Fig. 1, panel F). PCR-RFLP screening of mutations listed in Table 1 did not reveal any pattern that was similar to those in the 200 normal controls.
###end p 15
###begin title 16
Clinical features
###end title 16
###begin p 17
###xml 36 43 36 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
Clinical features are summarized in Table 2. The 10 MC patients with CLCN1 mutations included nine males and one female, whose ages at presentation and onset were 22.5 yr (range 1-40 yr) and 9.5 yr (range 1-28 yr), respectively. Family history was compatible with autosomal dominant inheritance in three patients. Another two patients had affected sibling(s), which was suggestive of autosomal recessive inheritance. In the other patients, there was no significant family history of any neuromuscular disease.
###end p 17
###begin p 18
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 617 625 <span type="species:ncbi:9606">patients</span>
###xml 740 747 <span type="species:ncbi:9606">patient</span>
###xml 770 777 <span type="species:ncbi:9606">patient</span>
###xml 810 817 <span type="species:ncbi:9606">patient</span>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">patients</span>
###xml 945 953 <span type="species:ncbi:9606">patients</span>
###xml 1199 1206 <span type="species:ncbi:9606">patient</span>
###xml 1317 1325 <span type="species:ncbi:9606">patients</span>
###xml 1336 1343 <span type="species:ncbi:9606">Patient</span>
All patients complained of intermittent myotonic stiffness involving the limbs and trunk, which predominantly initially affected the lower extremities. The stiffness was always provoked by sudden initiation of movement after rest (such as grasping, walking, running, standing up, and lifting objects) and dissipated shortly after repeated use of the affected musculature. In three patients (patients 1, 8, and 9), myotonic stiffness affected facial musculature in addition to limbs and trunk, either as chewing difficulty, facial stiffness, speech disturbance, or eye opening difficulty in variable combinations. Two patients considered that there was a worsening of their symptoms by certain physiological factors including cold exposure (patient 6, p.S189C mutant and patient 7, p.P480S mutant) and fasting (patient 7). Myotonia could be provoked by tapping on skeletal muscles or following a firm hand grip in all patients. In five patients (patients 1, 3, 4, 5, and 9), myotonia was also provoked by tapping of the tongue as the 'napkin ring' sign. The degree of myotonia-induced muscle stiffness was highly variable, from mild discomfort caused by intermittent leg stiffness a few times a day (patient 4) to frequent and severe focal or generalized muscle stiffness provoked by virtually every motion attempted (patients 1 and 9). Patient 1 also complained of an accompanying myalgic pain during attacks of myotonic stiffness.
###end p 18
###begin p 19
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 83 90 <span type="species:ncbi:9606">Patient</span>
###xml 730 738 <span type="species:ncbi:9606">Patients</span>
Four patients complained of muscle weakness in addition to the myotonic stiffness. Patient 1 (p.M609K mutant) initially experienced intermittent short lasting muscle weakness of limbs following myotonic stiffness beginning at 8-yr-of-age. His weakness became more frequent and longer-lasting, and constant muscle weakness began to develop from the age of 19. Initially, fixed weakness that arose in his hands and feet soon began to spread to other limb muscles. At age 20, his limb muscle power as graded by the modified Medical Research Council muscle power grading system was 4 in proximal/distal upper/lower limbs. His hand grip power as measured by a hand dynamometer was 9 kilograms on the right and 8 kilograms on the left. Patients 3 (p.M609K+p.G355R), 9 (p.S189C) and 10 (p.G523D) also had short-lasting muscle weakness following myotonic stiffness.
###end p 19
###begin p 20
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 202 209 <span type="species:ncbi:9606">patient</span>
###xml 211 218 <span type="species:ncbi:9606">patient</span>
Seven patients (70.0%) showed muscular hypertrophy that varied in both degree and distribution. Among them, patients 1 and 9 showed the most prominent generalized form of muscular hypertrophy. A female patient (patient 7) also showed mild muscle hypertrophy.
###end p 20
###begin p 21
###xml 602 609 602 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 65 72 <span type="species:ncbi:9606">patient</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 365 372 <span type="species:ncbi:9606">patient</span>
###xml 447 454 <span type="species:ncbi:9606">patient</span>
Needle electromyography was performed in all patients except for patient 5, and all showed evidence of abnormal muscle fiber excitability, mostly in the form of myotonic discharges, except in patients 6 and 7, who experienced showers of positive sharp waves instead. Muscle biopsy was performed in five patients and only two of them showed mild myopathic patterns; patient 1 displayed a few regenerating fibers with type 1 fiber predominance, and patient 7 displayed mild type 2B fiber atrophy. Several drugs including mexiletine, phenytoin, and caramabazepine were tried and showed various responses (Table 2).
###end p 21
###begin title 22
DISCUSSION
###end title 22
###begin p 23
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 163 169 163 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 516 517 516 517 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</underline>
###xml 524 530 524 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 785 786 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1209 1211 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 813 821 <span type="species:ncbi:9606">patients</span>
The present study identified six novel CLCN1 mutations from 10 unrelated Korean MC patients. The c.384G>A mutation located in the transmembrane region of helix B (Fig. 2) is expected to change the highly conserved amino acid methionine to isoleucine (p.M128I). A myotonia-associated mutation involving the same codon (M128V) has been reported previously (8). Another mutation, c.566C>G (S189C), present in two of the 10 patients (patients 6 and 9) is located in the highly conserved CLC-1 protein signature region (GSGIPE) (Fig. 2). Since this region is thought to be a chloride ion binding site, the introduction of the much larger sulfhydryl group of cysteine in place of the serine hydroxyl might be anticipated to have a significant effect on the conductance of the CLC-1 channel (9, 10). Since both of these patients showed an autosomal dominant inheritance pattern of disease, c.566C>G (p.S189C) is most likely associated with Thomsen's disease. Previously present, p.S189C had been evaluated as a site-directed mutant expressed in cultured tsA201 cells. However, the observation of a relatively normal chloride current fails to support a pathogenic role of the mutation in the development of myotonia (11).
###end p 23
###begin p 24
###xml 78 84 78 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 409 415 409 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 722 728 722 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1077 1083 1077 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1330 1332 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1502 1504 1499 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1851 1853 1848 1850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1998 2000 1995 1997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 2304 2306 2301 2303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 2307 2309 2304 2306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 983 991 <span type="species:ncbi:9606">patients</span>
The c.1117A>T mutation, which is located in the helix J transmembrane domain (Fig. 2), changes the codon for methionine to leucine (p.M373L). Since no pathogenic missense mutation has previously been found in helix J, this mutant will require functional study for the verification of its pathogenicity. Another new mutation, c.1438C>T (p.P480S), is located in the cytoplasmic loop connecting helices M and N (Fig. 2), where it changes the highly conserved amino acid proline to serine. Since three different missense mutations involving the same codon (p.P480T, p.P480L, and p.P480H) have been reported previously (12-14), its pathogenicity is almost certain. A novel mutation, c.1568G>A (p.G523D), is located in helix O (Fig. 2) at a glycine that is fairly conserved between different species. Since no pathogenic mutation has been identified in this area, its verification will also depend on functional study. Another novel mutation, c.1826T>A (p.M609K), which was present in two patients, is also notable. The mutated amino acid, methionine, is located at the CBS1 domain (Fig. 2) and is highly conserved between different CLC proteins as well as between different species. CBS (cystathione beta-synthase) domains are sequence motifs of approximately 60 amino acids that occur in CBS and many other proteins in all organisms (15). Recently, the CBS domains of CLC-1 have been suggested to function as sensors of cellular energy status that act by binding ATP, which is crucial for channel opening (16). Another study also showed that the structure of CBS domains from CLC channels is highly conserved, and mutations in CBS domains were suggested to affect protein-protein interactions within CLC protein subunits as well as between the two subunits of CBS dimers, thereby influencing the voltage dependence of gating by acting on the common gate (17). Only one missense mutation affecting the CBS1 domain (p.A659V) has been reported so far, but has not yet been verified by a functional study (13). Thus, the functional study of the presently-reported novel mutation c.1826T>A (p.M609K) could be important to elucidate the role of the CBS1 domain in channel function. Other presently identified mutations c.929C>T (p.T310M), c.949C>T (p.R317X), and c.1063G>A (p.G355R) have been previously reported (18-20).
###end p 24
###begin p 25
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 621 623 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 119 126 <span type="species:ncbi:9606">patient</span>
One of the interesting findings in our study was the apparent male predominance of MC in Korea. We had only one female patient and her disease was relatively mild. Although there is no direct evidence that males are more frequently affected than females, it seems clear that myotonia, both clinically and electrically, may be more pronounced in males, especially in the recessive form of disease (21-23). This gender difference in MC was not well-understood until recently, when the sex hormones testosterone, progesterone, and 17beta-estradiol were implicated in gender differences and pregnancy-related symptoms of MC (24).
###end p 25
###begin p 26
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 98 105 <span type="species:ncbi:9606">Patient</span>
###xml 387 394 <span type="species:ncbi:9606">patient</span>
Our patients showed a broad spectrum of clinical severity, consistent with a previous study (21). Patient 1 showed the most severe symptoms of the disease: marked muscular hypertrophy, severe myotonia, and fixed weakness of the limbs leading to significant impediment to daily life. Unfortunately, we could not determine whether the mode of inheritance was dominant or recessive in this patient, since no other family member was affected and only a single mutant allele (p.M609K) was identified.
###end p 26
###begin p 27
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 304 311 <span type="species:ncbi:9606">patient</span>
###xml 332 339 <span type="species:ncbi:9606">patient</span>
Patient 9 (p.S189C) is also noteworthy because of the exceptionally severe clinical features for an autosomal dominant MC: marked muscular hypertrophy, severe myotonia, and transient weakness. This might be related to the site of the mutation within the signature region of the channel. However, another patient with same mutation (patient 6) showed only a moderate degree of severity without muscular hypertrophy or transient weakness, suggesting that the type and location of the mutation is unlikely to be the sole determinant of clinical severity. Differential allelic expression might be responsible for this kind of phenotypic variability between individuals sharing same mutation (25).
###end p 27
###begin p 28
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
Two of our patients complained of worsening of myotonia during cold exposure (patients 6, 7) and fasting (patient 7). So far, many stimuli within normal physiological range have been implicated as aggravating factors for myotonia, including cold temperature, pregnancy, emotional stress, fasting, and fatigue (8, 26). Cold sensitivity had been considered as one of the features differentiating paramyotonia congenita from other nondystrophic myotonias, but some clinical and electromyographic studies have confirmed that it is also common in patients with MC (8, 14, 27, 28). It has been suggested that the presence of cold sensitivity might be related to the type of CLCN1 mutation (14, 28). Our study further supports the growing consensus that cold sensitivity should not be considered as a clinical feature unique to paramyotonia congenita among different types of nondystrophic myotonias.
###end p 28
###begin p 29
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
While many patients with MC can manage their lives without medication, treatment can be of help when myotonic stiffness interferes with everyday activity and is associated with pain. We tried various drugs including mexiletine, carbamazepine, or phenytoin in our patients, and the response was highly variable. Of the four patients treated with mexiletine, three patients showed dramatic improvement of myotonic stiffness while the improvement in one was moderate, while in other patients no treatment was effective. Although mexiletine is currently considered as a drug of choice in patients with MC (29, 30), it has no known direct effect on chloride channels and may simply attenuate myotonic stiffness by blocking, and thereby reducing the availability of, some sodium channels for action potential production (21).
###end p 29
###begin p 30
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
In conclusion, we report six novel CLCN1 mutations in Korean patients with MC, and suggest their clinical features are quite variable even between patients sharing a same mutation.
###end p 30
###begin title 31
ACKNOWLEDGMENT
###end title 31
###begin p 32
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
We would like express our thanks to Professor Allan Bretag from the Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, for his valuable comments on our new CLCN1 mutations.
###end p 32
###begin p 33
###xml 77 134 77 134 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Korean Government (MOEHRD, Basic Research Promotion Fund)</funding-source>
###xml 136 155 136 155 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRF-2007-331-E00201</award-id>
This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2007-331-E00201).
###end p 33
###begin article-title 34
###xml 63 68 <span type="species:ncbi:9606">human</span>
The skeletal muscle chloride channel in dominant and recessive human myotonia
###end article-title 34
###begin article-title 35
Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita)
###end article-title 35
###begin article-title 36
ClC-1 chloride channel mutations in myotonia congenita: variable penetrance of mutations shifting the voltage dependence
###end article-title 36
###begin article-title 37
###xml 28 33 <span type="species:ncbi:9606">human</span>
Genomic organization of the human muscle chloride channel CIC-1 and analysis of novel mutations leading to Becker-type myotonia
###end article-title 37
###begin article-title 38
Molecular pathophysiology of voltage-gated ion channels
###end article-title 38
###begin article-title 39
Myotonia congenita
###end article-title 39
###begin article-title 40
Myotonia levior is a chloride channel disorder
###end article-title 40
###begin article-title 41
Decrement of compound muscle action potential is related to mutation type in myotonia congenita
###end article-title 41
###begin article-title 42
X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity
###end article-title 42
###begin article-title 43
Gating the selectivity filter in ClC chloride channels
###end article-title 43
###begin article-title 44
###xml 44 49 <span type="species:ncbi:9606">human</span>
Residues lining the inner pore vestibule of human muscle chloride channels
###end article-title 44
###begin article-title 45
Myotonia caused by mutations in the muscle chloride channel gene CLCN1
###end article-title 45
###begin article-title 46
Novel chloride channel gene mutations in two unrelated Japanese families with Becker's autosomal recessive generalized myotonia
###end article-title 46
###begin article-title 47
Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions
###end article-title 47
###begin article-title 48
The structure of a domain common to archaebacteria and the homocystinuria disease protein
###end article-title 48
###begin article-title 49
CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations
###end article-title 49
###begin article-title 50
Functional and structural conservation of CBS domains from CLC chloride channels
###end article-title 50
###begin article-title 51
Transient weakness and compound muscle action potential decrement in myotonia congenita
###end article-title 51
###begin article-title 52
###xml 35 40 <span type="species:ncbi:9606">human</span>
Spectrum of mutations in the major human skeletal muscle chloride channel gene (CLCN1) leading to myotonia
###end article-title 52
###begin article-title 53
Novel CLCN1 mutations with unique clinical and electrophysiological consequences
###end article-title 53
###begin article-title 54
Phenotypic variability in myotonia congenita
###end article-title 54
###begin article-title 55
Novel muscle chloride channel mutations and their effects on heterozygous carriers
###end article-title 55
###begin article-title 56
Electrical myotonia in heterozygous carriers of recessive myotonia congenita
###end article-title 56
###begin article-title 57
Non-genomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita
###end article-title 57
###begin article-title 58
Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype
###end article-title 58
###begin article-title 59
Myotonia congenita in pregnancy
###end article-title 59
###begin article-title 60
Comparative efficacy of repetitive nerve stimulation, exercise, and cold in differentiating myotonic disorders
###end article-title 60
###begin article-title 61
Cold extends electromyography distinction between ion channel mutations causing myotonia
###end article-title 61
###begin article-title 62
Improved therapy of myotonia with the lidocaine derivative tocainide
###end article-title 62
###begin article-title 63
Therapy in myotonic disorders and in muscle channelopathies
###end article-title 63
###begin p 64
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 83 84 83 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 107 108 107 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 132 133 132 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 156 157 156 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 181 182 181 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
Chromatograms of novel mutations identified in the study. (A) c.384G>A (p.M128I), (B) c.566C>G (p.S189C), (C) c.1117A>T (p.M373L), (D) c.1438C>T (p.480S), (E) c.1568G>A (p.G523D), (F) c.1826T>A (p.M609K).
###end p 64
###begin p 65
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Two-dimensional representation of the structure of a CLC subunit (9) showing the locations of mutations identified in this study.
###end p 65
###begin p 66
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
Mutations of CLCN1 identified in the study
###end p 66
###begin p 67
PCR-RFLP, polymerase chain reaction and restriction length polymorphism analysis.
###end p 67
###begin p 68
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLCN1</italic>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Clinical features of the patients with CLCN1 mutation
###end p 68
###begin p 69
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 360 383 360 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">Colding-J&#248;rgensen, 2005</xref>
###xml 386 392 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*Severity of myotonia congenita was graded as follows; (1) no symptoms, but unequivocal myotonia at examination, (2) mild (and/or fluctuating) symptoms, (3) pronounced myotonia, but no transient weakness, (4) pronounced myotonia with transient weakness,but without dystrophic features, and (5) pronounced myotonia, transient weakness, and dystrophic features (Colding-Jorgensen, 2005); daggerResponse to treatment was judged as follows: excellent; complete or near-complete abolition of symptom, good; >70% reduction of frequency and duration of myotonic stiffness, fair; <70% and >30% reduction of frequency and duration of myotonic stiffness, poor; <30% reduction of frequency and duration of myotonic stiffness.
###end p 69
###begin p 70
M, male; F, female; AR, autosomal recessive; AD, autosomal dominant; IU, international unit; ND, not done; PSWs, showers of positive sharp waves with or without complex repetitive discharges.
###end p 70

